title: Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
abstract: Objectives. To observe changes in blood glycemic variations and oxidative stress level before and after dapagliflozin treatment in patients with newly diagnosed T2DM.Methods. This was a randomized, double-blind, placebo-controlled, phase 3 trial. A total of 28 patients with newly diagnosed T2DM with HbA1clevels of 7.5-10.5% were randomly selected to receive dapagliflozin or placebo treatment for 24 weeks. After baseline data were collected, we analyzed glycemic variations and plasma 8-iso PGF2αlevel at baseline and at the endpoint. Primary outcome was the changes of mean amplitude glycemic excursion (MAGE) within groups.Results. After 24-week dapagliflozin therapy, our data showed the significant improvement of MAGE with dapagliflozin therapy (P= 0.010). Compared with control group, patients in dapagliflozin group exhibited reduction in 24-hour MBG (P= 0.026) and lower mean plasma glucose concentrations, especially during periods from 2400 to 0200 and 1300 to 1800 (P< 0.05, resp.). In addition, plasma 8-iso PGF2αlevel was notably decreased in the treatment group compared to the control group (P= 0.034).Conclusions.In conclusion, this study shows the ability of dapagliflozin to improve glycemic variations and associate with reduction of oxidative stress in patients with T2DM, which may benefit the cardiovascular system.
authors.affiliation: Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Feng-Fei
authors.initials: FF
authors.lastname: Li
authors.affiliation: Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Gu
authors.initials: G
authors.lastname: Gao
authors.affiliation: Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Li
authors.affiliation: Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Hong-Hong
authors.initials: HH
authors.lastname: Zhu
authors.affiliation: Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Xiao-Fei
authors.initials: XF
authors.lastname: Su
authors.affiliation: Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Jin-Dan
authors.initials: JD
authors.lastname: Wu
authors.affiliation: National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore.
authors.forename: Lei
authors.identifier: 0000-0001-5039-6224
authors.initials: L
authors.lastname: Ye
authors.affiliation: Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Jian-Hua
authors.identifier: 0000-0001-9383-2559
authors.initials: JH
authors.lastname: Ma
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D015237:Dinoprost / Q000031:analogs & derivatives / Q000378:metabolism; D004311:Double-Blind Method; D005960:Glucosides / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D018384:Oxidative Stress
chemical_list: D001559:Benzhydryl Compounds; D001786:Blood Glucose; D015237:Dinoprost; D005960:Glucosides; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human; C529054:dapagliflozin; C075750:8-epi-prostaglandin F2alpha